Persistent Effect of Arimoclomol in Patients with Niemann-Pick Disease Type C: 24-Month Results from an Open-Label Extension of a Pivotal Phase 2/3 Study

MLA

Eugen Mengel, et al. “Persistent Effect of Arimoclomol in Patients with Niemann-Pick Disease Type C: 24-Month Results from an Open-Label Extension of a Pivotal Phase 2/3 Study.” Abstracts of the 46th Annual Meeting of the Society for Neuropediatrics, Oct. 2021. EBSCOhost, https://doi.org/10.1055/s-0041-1739640.

APA

Eugen Mengel, Anna Tylki-Szymańska, Marie Aavang Geist, Esther M. Maier, Bénédicte Héron, Thomas Kirkegaard, Matthias Gautschi, Anne Katrine Andreasen, Simon Day, Stephanie Grunewald, Nikolaj H.T. Petersen, Mireia del Toro, Christine í Dali, Federica Deodato, Thomas Hansen, Marc C. Patterson, Saikat Santra, Paul Harmatz, Thomas Blaettler, … Agathe Roubertie. (2021). Persistent Effect of Arimoclomol in Patients with Niemann-Pick Disease Type C: 24-Month Results from an Open-Label Extension of a Pivotal Phase 2/3 Study. Abstracts of the 46th Annual Meeting of the Society for Neuropediatrics. https://doi.org/10.1055/s-0041-1739640

Chicago

Eugen Mengel, Anna Tylki-Szymańska, Marie Aavang Geist, Esther M. Maier, Bénédicte Héron, Thomas Kirkegaard, Matthias Gautschi, et al. 2021. “Persistent Effect of Arimoclomol in Patients with Niemann-Pick Disease Type C: 24-Month Results from an Open-Label Extension of a Pivotal Phase 2/3 Study.” Abstracts of the 46th Annual Meeting of the Society for Neuropediatrics, October. doi:10.1055/s-0041-1739640.